Updated on 7 February 2013
Dr Perry has over 25 years of successful pharmaceutical and biotech management and development experience
Singapore: Regenerative medicine company Avita Medical, listed on ASX, has appointed Dr Michael S Perry, vice president and senior global program head, Stem Cell Therapy at Novartis Pharmaceuticals, to the company's board of directors. Dr Perry has over 25 years of successful pharmaceutical and biotech management and development experience.
Mr Dalton Gooding, chairman, Avita Medical, said, "Michael has extraordinary biotech and business expertise, and we are delighted that he is joining Avita's board of directors."
Dr Perry currently serves as vice president and senior global program head, Stem Cell Therapy at Novartis Pharmaceuticals. Based in the US, he has previously served as the global head of R&D at Baxter Healthcare, president, Cell & Gene Therapy at Novartis affiliates SyStemix and Genetic Therapy, VP Regulatory Affairs at Sandoz Pharmaceuticals, director of Regulatory Affairs at Schering-Plough, and chairman, CEO or CMO at several early-stage biotech companies.
From 2005 to 2012, Dr Perry was a venture partner with Bay City Capital, a California-based venture capital firm managing over $1.6 billion invested predominantly in life science companies. "Michael brings a wealth of experience and scientific acumen as well as the insights that come from running successful large global divisions and emerging start-ups. Michael will be a great addition to our board and I am delighted to be working with him," said Dr William Dolphin, Avita chief executive officer.
"I am honored to join the Avita board and work with this exceptional team," Dr Perry said. "Avita has the potential to make a significant impact in the field of regenerative medicine and I look forward to sharing my experiences and contributing to the future direction and growth at this early stage in the company's history."
In addition to Avita Medical, Dr Perry currently serves on the board of two publicly held companies.